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Leukocyte infiltration, a hallmark of renal diseases, is
orchestrated in part by the actions of chemokines. The
chemokine CXCL8/interleukin (IL)-8 is expressed during renal
diseases and allograft rejection, whereas the corresponding
receptor CXCR1 has not been described previously.
Expression of CXCR1 was characterized in peripheral blood
using multicolor fluorescence-activated cell sorter analysis
(FACS). CXCR1 was localized in 81 formalin-fixed, paraffin-
embedded renal specimens by immunohistochemistry using
a monoclonal antibody against human CXCR1. Included were
biopsies with crescentic glomerulonephritis (CGN, n¼ 22),
immunoglobulin (Ig) A nephropathy (n¼ 15),
membranoproliferative glomerulonephritis (MPGN, n¼ 17),
lupus nephritis (n¼ 12), membranous nephropathy (n¼ 11),
and non-involved parts of tumor nephrectomies (n¼ 4).
Consecutive tissue sections of human tonsils, allograft
explants, and renal biopsies were stained for CD15- and
CD68-positive cells. Expression of CXCR1 and CXCL8/IL-8
mRNA was quantified by real-time reverse
transcriptase-polymerse chain reaction of microdissected
renal biopsies (n¼ 35) of the same disease entities. By
FACS CXCR1 expression was found on polymorphonuclear
CXCR1 expression by polymorphonuclear leukocytes (PMNs),
natural killer cells, and a subpopulation of monocytes. By
immunohistochemistry, CXCR1 expression was found on
infiltrating inflammatory cells (predominantly PMNs), as well
as on intrinsic renal cells (arterial smooth muscle cells,
endothelial cells of peritubular capillaries). The distribution
pattern of CXCR1 differed between disease entities. The
highest numbers of glomerular CXCR1-positive cells were
present in biopsies with MPGN, followed by lupus nephritis,
and CGN. CXCR1 might be involved in the recruitment of
PMNs to the glomerular tuft, which could be targeted by
CXCR1-blocking agents.
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The infiltration of glomeruli and other renal compartments
by inflammatory cells is a hallmark of glomerulonephritis
(GN), and correlates with renal function and prognosis.1
Chemokines are members of a family of chemotactic
cytokines that play central roles in the recruitment of specific
subsets of leukocytes to sites of inflammation or specific
microenvironments.2–6 CXCL8/IL-8 binds to and signals
through the chemokine receptors CXCR1 and CXCR2. In
addition, CXCL8/IL-8 binds to the Duffy antigen/receptor for
chemokines, a promiscuous chemokine-binding protein
expressed on peritubular capillaries in inflamed kidneys.7–9
CXCL8/IL-8 was the first leukocyte selective chemokine to
be identified and its corresponding receptors were the first
chemokine receptors to be defined.7,10,11 In vitro studies
demonstrated that mesangial cells, podocytes, tubular
epithelial cells, and fibroblasts could be potential sources
for CXCL8/IL-8.6,12,13 The expression of CXCL8/IL-8 by
intrinsic renal cells is induced in vitro by proinflammatory
cytokines and growth factors that are upregulated in
glomerular diseases.6,14–16 In vivo treatment with an
CXCL8/IL-8-blocking antibody reduced glomerular neutro-
phil accumulation and proteinuria in an acute immune-
complex GN in rabbits.17,18 Induction of CXCL8/IL-8 has
also been described in a model of bilateral renal ischemia.19
In human glomerular diseases, urinary excretion of CXCL8/
IL-8 was found to be increased in patients with IgA
nephropathy, acute GN, lupus nephritis, MPGN, and
cryoglobulinemia.20 CXCL8/IL-8 mRNA expression was
localized to the glomerular tuft and parietal epithelial cells,
as well as to tubular epithelial cells, smooth muscle cells,
endothelial cells, and some interstitial cells in normal human
kidneys, but was found to be reduced during GN.21
In contrast to the data on CXCL8/IL-8, the expression of
the corresponding receptors CXCR1 and 2, and the cells
attracted by CXCL8/IL-8 during renal diseases has not been
addressed. Cells which might be responsive to CXCL8/IL-8
include polymorphonuclear leukocytes (PMNs), natural
killer cells, a subset of T cells (CD8-positive with effector
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function, CD4-positive T cells in TH2 responses), dendritic
cells, mast cells, endothelial cells, and chondrocytes, all of
which have been shown to express CXCR1.7,22–31 Expression
of CXCR1 has also been described on podocytes in vitro and
in biopsy samples of membranous GN.32 The aim of the
current study was to characterize the distribution of CXCR1
in glomerular diseases, and to identify diseases with a high
number of CXCR1-positive inflammatory cells as potential
target diseases for therapeutic intervention using CXCR1
antagonists.
RESULTS
Establishment of the antibody against CXCR1 for the use in
immunohistochemistry
A commercial, monoclonal antibody against CXCR1 was
extensively tested for immunohistochemistry on formalin-
fixed, paraffin-embedded material. Antigen retrieval by
autoclaving resulted in a reproducible staining pattern on
human tonsils, whereas isotype controls were negative
(Figure 1a and c). In the tonsil, CXCR1 was found to be
expressed by PMNs, identified by the nuclear morphology
(Figure 1i), parallel staining with CD15 (Figure 1c and d),
and double immunofluorescence (Figure 1g and h). An
additional cell population expressing CXCR1 was found
predominantly in the center of follicles (Figure 1e). These
cells are not CD3 positive (by double fluorescence) and do
not match the pattern of the CD68-positive population on
consecutive sections.
All neutrophils, present in the whole blood population,
stained strongly for CXCR1 (mean fluorescence intensity of
450). In total, 50% of CD14þ cells were CXCR1 positive. The
majority of natural killer cells, characterized as CD56dim/
CD16high expressed CXCR1, while the CD16neg/dim natural
killer cells were negative. B cells (CD19þ ) and CD3þ T cells
were negative for CXCR1.
Cells isolated from tonsil had very few (0.1%) CXCR1-
positive cells. Most likely this is because of the isolation
procedure which apparently did not retrieve the myeloid
subset (2.9%, CD14þ , CD13þ , CD68þ , or CD209þ ).
Consistently with the pattern found in peripheral blood, B
cells (73%, CD19þor CD20þ ) and T cells (25%, CD3þ ) of
tonsil were CXCXR1 negative. The natural killer cell
population present in tonsil (0.8%) was of the CD16neg/dim
subtype and in accordance with the observation in peripheral
blood was also CXCR1 negative. The population of CXCR1-
positive intrafollicular cells found by immunohistochemistry
therefore remains poorly defined. The distribution would be
consistent with a B-cell population, but this was not
confirmed by flow cytometry. Some cells might represent a
subset of CD209þ dendritic cells which are found in the
tonsil follicles.33,34 Besides inflammatory cells, CXCR1
expression was prominent on smooth muscle cells of arteries,
whereas expression on endothelium of tonsils was not
detectable (Figure 1c and h).
In renal biopsies, a good morphological and significant
numerical correlation was found between CXCR1- and
CD15-positive cells in glomeruli (Po0.0001). No morpho-
logical correlation was found between the pattern of CD68-
positive monocytes/macrophages and CXCR1-positive cells,
also based on the relatively high numbers of CD68-positive
cells, a small population positive for CXCR1 could not be
excluded. The number of both glomerular and interstitial
CD68-positive cells greatly outnumbered the CXCR1- and
CD15-positive cells.
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Figure 1 | CXCR1 expression in human tonsils. Immunohisto-
chemistry on consecutive sections of human tonsils, using isotype
(a) IgG, (b) anti-CD68, (c, e, h, i) anti-CXCR1, and (d, f) anti-CD15
monoclonal antibodies (a–d, original magnification  100; e, f,
original magnification  200; g, h, original magnification  400;
i, original magnification  1000). No color product is detectable in
the IgG control (a). Note the positive cells in the periphery of a large
vessel, with similar patterns for (c) CXCR1- and (d) CD15-positive
PMNs, but not (b) CD68-positive macrophages. In addition to (arrow
in e, f) CD15-positive cells, (e) CXCR1 is expressed by cells within
follicles. At a high magnification (i, original magnification  1000),
some positive cells can be clearly identified as PMNs, according to the
nuclear structure (arrowhead). Double-immunofluorescence for
(g) CD15 and (h) CXCR1 demonstrates a double positive PMN (arrow)
in an artery with CXCR1-positive smooth muscle cells (arrowhead).
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Expression of CXCR1 in normal renal tissue
Areas not involved by the tumor from four nephrectomies
were used to characterize the expression of CXCR1 in
‘normal’ renal tissue (Figure 2). Expression of CXCR1 was
found on only a small number of cells in the control kidneys
(both on intrinsic renal cells as well as on infiltrating
leukocytes). Scattered, circulating CXCR1-positive cells were
found in glomerular or peritubular capillaries (Figure 2a and
b). A prominent expression of CXCR1 was present on
smooth muscle cells of small and medium-sized arteries in all
four specimens (Figure 2c and d). Positive vessels (5–18) were
found in the 20 high-power fields evaluated. The number of
positive vessels seems to be higher as compared to biopsies
from diseased kidneys (Table 1). CXCR1 expression was
found on endothelial cells of a small number of peritubular
capillaries (Figure 2e). On rare occasions, positive staining of
cells of Bowman’s capsule (Figure 2f) or glomerular epithelial
cells was detectable (Figure 2g). Tubular epithelial cells were
CXCR1 negative.
CXCR1 expression in MPGN
Included were 17 biopsies with a membranoproliferative
pattern of glomerular injury. These biopsies contained the
highest numbers of CXCR1-positive cells within glomeruli
(Figures 3 and 4a–c). This is consistent with the observation
that it was the disease that showed the highest number of
glomerular CD15-positive cells (Table 1). Most of the
glomerular cells were PMNs according to the morphology
of the nuclei and the distribution (Figure 4c and d). CXCR1-
positive cells were sometimes accentuated in the periphery of
the glomerular tuft (Figure 4a and c). Of the 17 biopsies, 13
demonstrated a strong glomerular infiltration by CXCR1-
positive cells. Additionally, these biopsies demonstrated a
conspicuous interstitial accumulation of CXCR1-positive
cells (Figure 4b).
In contrast, the number of CXCR1-positive vessels was
very low. Only five biopsies contained positive vessels, with
only 1–2 positive vessels per 20 high-power fields (Table 1).
CXCR1 expression in CGN
Twenty-two biopsies with crescentic glomerulonephritis
(CGN) were included in the study. The number of CXCR1-
positive infiltrating cells was high within both glomeruli and
the tubulointerstitium (Figure 5a, b and e). CXCR1-positive
cells were found to be accumulated within the remaining
glomerular tuft and were rarely present within extracapillary
crescents (Figure 5a and b). Some biopsies demonstrated a
prominent accumulation of CXCR1-positive cells within the
interstitium, predominantly in peritubular capillaries (Figure
5e and f). In nine biopsies CXCR1 expression was predo-
minantly found by infiltrating cells in the interstitium, 13
demonstrated expression primarily in glomeruli or in both
the interstitium and glomeruli. Only six of the 22 biopsies
demonstrated staining of arterial smooth muscle cells and the
numbers of positive vessels (between 1 and 3 per 20 high-
power fields) were low. A good morphological correlation was
found between interstitial CXCR1-positive infiltrating cells and
CD15- positive cells (Figure 5e and f). CXCR1-positive cells
were greatly outnumbered by CD68-positive cells in glomeruli
and the tubulointerstitium (Figure 5c and d).
CXCR1 expression in lupus nephritis
Twelve biopsies from patients with lupus nephritis (three
type III, nine type IV) were examined. The overall number of
CXCR1-positive infiltrating cells was high and similar to
what was seen in biopsies with CGN (Figures 5 and 6).
CXCR1-positive inflammatory cells were common in (Figure
6c) and around the glomeruli (Figure 6a and b). Most of the
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Figure 2 | CXCR1 expression in well preserved renal tissue.
Immunohistochemistry on sections of tumor nephrectomies using
the monoclonal anti-CXCR1 antibody (a, b, original magnification
 200; c–g, original magnification  400). Please note the low
number of CXCR1-positive circulating cells in (a) glomerular
capillaries or (b) peritubular capillaries (arrowhead). A high number of
CXCR1-positive smooth muscle cells was present in (c, d) arteries and
arterioles. (e, arrowhead) Endothelial cells of a low number of
peritubular capillaries were positive for CXCR1. (f, arrowhead) Only
occasionally were cells of Bowman’s capsule or (g, arrowhead)
glomerular epithelial cells positive for CXCR1
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samples demonstrated either a mixed pattern of staining or
with a principle expression by infiltrating cells within the
glomeruli. Smooth muscle cells of arterioles were commonly
positive for CXCR1 (Figure 6a). In half of the biopsies,
vascular smooth muscle cell expression of CXCR1 was
detectable, with a range between one and 20 positive vessels
per 20 high-power fields (Table 1).
CXCR1 expression in IgA nephropathy
According to the subclassification of IgA nephropathy by
Haas,35 one biopsy was subclass II, five were subclass III, and
nine biopsies were of subclass IV. In these biopsies, overall
Table 1 | Mean number of CXCR1-positive cells or vessels in the different disease entities
Disease
Mean number of
CXCR1 positive
interstitial cells
Mean number of
CXCR1 positive
cells per glomerulus
Mean number of
CXCR1 positive
vessels
Mean number of
CD15 positive
interstitial cells
Mean number of
CD15 positive cells
per glomerulus
Mean number of
CD68 positive cells
per glomerulus
Membr N 0.5170.1 0.4270.1 1.8270.77 2.1471.07 0.670.26 2.3470.37
IgA N 0.770.16 0.8370.23 2.3370.30 1.1970.25 0.8470.37 3.9370.87
Lupus N 1.470.49 1.3670.26 3.1771.67 1.1370.22 2.370.63 8.2671.48
CGN 1.1770.15 1.2570.4 0.4170.42 4.870.74 3.370.88 5.6170.91
MPGN 1.470.51 2.4570.43 0.4770.21 2.1570.56 5.570.96 10.6371.84
CGN, crescentic GN; IgA N, IgA nephropathy; Lupus N, lupus nephritis; Membr N, membranous nephropathy; MPGN, membranoproliferative GN.
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Figure 3 | Mean number CXCR1-positive glomerular cells in the
studied disease entities. MPGN vs Membr N, Po0.01; Membr N,
membranous nephropathy; IgA N, IgA nephropathy; CGN, crescentic
GN; Lupus, lupus nephritis; MPGN, membranoproliferative GN.
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Figure 4 | CXCR1 expression in MPGN. Immunohistochemistry on
sections of biopsies with (a–d) MPGN using the (a, b, c) monoclonal
anti-CXCR1 antibody or (d, original magnification  400) anti-CD15.
(a, c) MPGN is the disease entity with the highest number of
CXCR1-positive infiltrating cells within glomeruli. (b) Illustrates the
high number of CXCR1-positive cells within the tubulointerstitium.
(c and d) Consecutive sections of a glomerulus illustrating the
corresponding patterns of CD15- and CXCR1-positive cells.
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Figure 5 | CXCR1 expression in CGN. Immunohistochemistry on
sections of biopsies with crescentic GN using the (a–c, e) monoclonal
anti CXCR1, (d) anti-CD68, and (f) anti-CD15 (a, b, e, f, original
magnification  200; c, d, original magnification  400). (a and b)
Illustrate the high number of CXCR1-positive cells in glomeruli. (c and
d) Demonstrate that the pattern of (c) CXCR1 is different to the
distribution of (d) CD68-positive monocytes/macrophages (on
consecutive sections). Please note the low number of CXCR1-positive
cells in this case, outnumbered by CD68-positive cells. Monocytes/
macrophages demonstrate a different pattern, particularly within the
tubulointerstitium. (e and f) Illustrate the similar distribution pattern
of interstitial (e) CXCR1- and (f) CD15-positive infiltrating cells.
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number of CXCR1-positive infiltrating cells was low
(Figure 3). Scattered positive cells were found in glomerular
and peritubular capillaries. Six cases demonstrated arterial
smooth muscle staining (with 1–13 positive vessels per 20
high-power fields). The number of CXCR1-positive cells did
not differ between subclass III and subclass IV (according to
the classification by Haas M35).
Expression of CXCR1 in membranous GN
All 11 biopsies with a membranous nephropathy contained a
low number of CXCR1-positive cells, similar to that seen in
biopsies with IgA nephropathy (Figure 3). Four biopsies
demonstrated 4–6 positive vessels per 20 high-power fields.
CXCL8/IL-8 and CXCR1 mRNA expression in renal biopsies
To further study the mRNA expression of CXCL8/IL8 and
CXCR1, we performed real time reverse transcriptase-
polymerse chain reaction on microdissected renal biopsies.
Expression was normalized to 18S ribosomal RNA. The
amount of CXCL8/IL-8 mRNA demonstrated a strong
variation between the groups tested (Figure 7). The most
prominent expression of CXCL8/IL-8 in the glomerular
compartment was found in biopsies with CGN, IgA
nephropathy, and lupus nephritis (Figure 7, upper left).
Consistently, CGN was the disease with the strongest
expression of CXCR1 within glomeruli (Figure 7, lower left).
Within the tubulo-interstitial compartment, MPGN and
lupus nephritis demonstrated the highest expression of both
the ligand CXCL8/IL-8 as well as the corresponding receptor
CXCR1.
DISCUSSION
Glomerular accumulation of CXCR1-positive infiltrating cells
was most prominent in three diseases, that is, MPGN, CGN,
and lupus nephritis. Both the distribution of CD15-positive
cells on serial sections and the nuclear morphology of
CXCR1-positive cells was consistent with PMNs. We also
demonstrated the expression of CXCL8/IL-8 and CXCR1
mRNA in glomeruli with CGN and lupus nephritis. Excretion
of CXCL8/IL-8 has been described in the urine of patients
with acute GN, lupus nephritis, and MPGN.20
Unexpectedly, MPGN was found to be the disease with the
highest numbers of CXCR1-positive infiltrating cells within
glomeruli. Although accumulation of PMNs in MPGN has
been described (‘exudative phase’), the potential role of these
cells in this disease is largely unexplored.36 MPGN is a
morphological entity characterized by increased glomerular
cellularity (via proliferation of intrinsic cells and recruitment
of leukocytes), thickening, and double contours of the
basement membrane.37 Accumulation of infiltrating inflam-
matory cells, particularly in cases associated with cryoglobu-
lins, has been well described, but the majority of these cells
have been identified as monocytes/macrophages.36,38 The
authors mention that a ‘moderate’ infiltration of neutrophils
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Figure 6 | CXCR1 expression in lupus nephritis and membranous
nephropathy. Immunohistochemistry on sections of biopsies with
(a–e) lupus nephritis and with (f) membranous nephropathy using
the (a–c, e, f) monoclonal anti-CXCR1 antibody, or a (d; a original
magnification  200) monoclonal anti-CD68 antibody (b–f original
magnification  400). (a) Illustrates the CXCR1-positive periglomer-
ular infiltrate (star) and positive smooth muscle cells (arrowhead,
compare with b). (c and d) Consecutive sections of the same
glomerulus which illustrates that CD68-positive monocytes/macro-
phages outnumber CXCR1-positive cells. (e) A prominent CXCR1-
positive interstitial infiltrate is illustrated (some CXCR1-positive cells
infiltrate the tubular epithelium, arrowhead). (f) CXCR1-positive cells
were only occasionally seen in membranous nephropathy.
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Figure 7 | CXCL8/IL-8 (upper panel) and CXCR1 (lower panel)
mRNA expression in renal biopsies microdissected into
glomeruli (left) and the tubulo-interstitial (right) compartment
(Membr N: membranous nephropathy, IgA N: IgA nephropathy,
CGN: crescentic GN, Lupus: lupus nephritis, MPGN: membrano-
proliferative GN).
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was commonly found in type I MPGN.36 Furthermore, an
increased number of PMNs has been described in glomeruli
in about a third of the cases.39 It was rather unexpected that
13 out of 17 biopsies with an MPGN pattern of injury
demonstrated a strong glomerular accumulation of CXCR1-
positive cells. The biopsies were randomly chosen according
to the availability of remaining material. Based on experi-
mental studies, neutrophil recruitment is thought to be an
early event in the inflammation cascade during GN. In
human MPGN, the accumulation of PMNs appears to occur
over a longer period as these cells can be detected in
randomly chosen renal biopsies. A pathogenetic role of
CXCR1-positive PMNs can be easily envisioned as these cells
are a rich source for reactive oxygen species, proteases
(degrading extracellular matrix including glomerular base-
ment membrane), and cytokines promoting cellular activa-
tion and further recruitment of inflammatory cells.40,41 This
is mainly based on animal models and further studies in
human MPGN are clearly needed.
A role for CXCL8/IL-8 in lupus nephritis has been
suggested by Rovin et al.42 This group identified polymorph-
isms in the CXCL8/IL-8 promoter region and the IL-8-845C
polymorphism was more common in African Americans with
severe lupus nephritis.42 Unfortunately, to the best of our
knowledge, the functional consequences of this polymorph-
ism are not known at present. In contrast to the data
presented by Wada20 who described an increased excretion of
CXCL8/IL-8 in the urine of patients with lupus nephritis,
Rovin et al.43 could not demonstrate increased CXCL8/IL-8
excretion in this patient group.
The role of CXCL8/IL-8 in antineutrophil cytoplasmic
autoantibody-associated GN has been addressed by Cockwell
et al.44 Expression of CXCL8/IL-8 was described within
glomeruli in segmental lesions, crescents and parietal
epithelial cells, and the protein colocalized with infiltrating
neutrophils.44 Anti-neutrophil cytoplamic antibodies-stimu-
lated neutrophils released large amounts of CXCL8/IL-8,
which prevented neutrophil transmigration in an in vitro
assay.44 Cockwell et al.44 found an accumulation of
neutrophils within glomerular capillaries as well as in the
tubulointerstitium, very similar to the general distribution of
CXCR1 staining demonstrated in our current study. Several
groups have demonstrated a prominent accumulation of
neutrophils in biopsies from patients with CGN, both in
glomeruli and the tubulointerstitium consistent with our
results.45,46 In addition, PMNs have been extensively studied
as the antigen source in anti-neutrophil cytoplamic anti-
bodies-associated vasculitis, but the role of PMNs as
infiltrating cells in CGN has not been widely addressed.45
Interestingly, the three entities characterized by the highest
numbers of CXCR1-positive cells are diseases which also
demonstrate prominent recruitment of monocytes/macro-
phages to glomeruli. The recruitment of CXCR1-positive
PMNs could be an early event, and might promote down-
stream recruitment of macrophages. Macrophages might also
be involved in the clearance of apoptotic PMNs, as described
in model systems.47 On the other hand, in a model of lung
injury, another amplification loop has been described in
which the presence of monocytes significantly accelerated
and increased alveolar neutrophil accumulation.48 Such a
mechanism would explain the finding of CXCR1-positive
PMNs in glomeruli of chronic MPGN. Here, we suggest a
model in which waves of PMNs are recruited to glomeruli in
the course of chronic glomerular diseases (particularly in
those with a prominent accumulation of macrophages).
Blocking CXCR1 in glomerular diseases might be a new
therapeutic approach in MPGN, lupus nephritis, and CGN.
Repertaxin is a small molecule, noncompetitive allosteric
inhibitor of CXCR1 and CXCR2.49 This substance locks
CXCR1 in an inactive conformation and prevents signaling.
Recruitment of PMNs into the reperfused liver was blocked
by repertaxin in a rat model of ischemia–reperfusion injury.49
Repertaxin has been used in phase I clinical studies and was
described as safe and well tolerated.49 Other CXCR1
antagonists are under investigation.50
In addition to inflammatory cells, CXCR1 was also found
to be expressed by intrinsic renal cells. By immunohisto-
chemistry in normal human tissue, a strong reactivity on
smooth muscle cells of a subset of small and medium-sized
arteries was demonstrated. The number of CXCR1-positive
arteries was high in normal control tissue, whereas it
appeared to be lower during GN. Expression of CXCR1 by
smooth muscle cells has not been described in the literature
and therefore needs to be confirmed using other methods. In
contrast to the positive staining of smooth muscle cells,
endothelial cells of arteries demonstrated no CXCR1 expres-
sion. Positive staining of endothelial cells was found on a low
number of peritubular capillaries. Again this staining was
pronounced in normal tissue as compared to biopsies with
glomerular diseases. For technical reasons, we cannot exclude
a low number of interstitial CXCR1-positive endothelial cells
in areas with strong tubulointerstitial inflammation. CXCR1-
positive podocytes where rarely seen in normal kidneys and
CXCR1 expression by podocytes did not correlate with
glomerular injury. CXCR1 expression has been demonstrated
in cultured podocytes, and in a case of membranous
nephropathy.32 None of the intrinsic renal cells demonstrated
an induction of CXCR1 during inflammatory injury. The
ligand CXCL8/IL-8 was clearly detectable on mRNA level and
might be involved in a house keeping function of CXCR1.21 A
note of caution should be added as renal biopsies only reflect
a snap shot in a complex disease course and the ‘well-
preserved’ tissue from tumor nephrectomies might not
represent the ‘normal’ situation.
In summary, this is the first study that demonstrates the
expression of CXCR1 by PMNs both in the glomerular and
tubulointerstitial renal compartment in glomerular diseases.
The most prominent glomerular accumulation of CXCR1
was found in MPGN, followed by lupus nephritis, and CGN.
The pathogenic role of these cells is still incompletely
understood, but these cells may represent a novel therapeutic
target.
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MATERIALS AND METHODS
Renal biopsies
A total of 81 human archival renal biopsies, from patients with CGN
(n¼ 22), IgA nephropathy (n¼ 15), MPGN (n¼ 17), lupus
nephritis (n¼ 12), membranous nephropathy (n¼ 11), and normal
renal tissue (derived from tumor nephrectomies, n¼ 4) were
included. Renal biopsies were fixed in 4% phosphate-buffered
formalin, embedded in paraffin. and cut at 2 mm. The histomorpho-
logic diagnosis was based on light microscopy, immunohistochemistry,
and electron microscopy.
Immunohistochemistry
The protocols for immunohistochemistry have previously been
described in detail.51 The primary antibody was diluted in 10% non-
fat dry milk and incubated overnight (anti-human CXCR1 (IL-8
RA), clone 42705.111, R&D Systems, Minneapolis, MN, USA). For
the description of the CXCR1-positive cell population, antibodies
against CD68-positive monocytes/macrophages (clone PG-M1,
DAKO, Glostrup, Denmark), CD3-positive T cells (clone CD3-12,
rat anti-human, Serotec, Oxford, UK), CD79-positive B cells (clone
JCB 117, Dako, Glostrup, Denmark), CD15-positive cells (clone
80H5, Immunotech, Marseille Frankreich), and smooth muscle
antigen (SMA, clone 1A4, Dako, Glostrup, Denmark) were used as
described previously.52
Immunofluorescence
Double fluorescence was used on human tonsils to further define the
CXCR1-expressing cell populations. After the biotinylated secondary
antibody slides were exposed to Streptavidin/fluorescein isothio-
cyanat (FITC) complex (Vector, Burlingame, CA, USA). Consecu-
tively, slides were rinsed, exposed to the rat-anti CD3 Antibody
(Serotec) followed by an anti-rat Cy3 antibody (Jackson Immunor-
esearch Laboratories Inc., West Grove, PA, USA). Double fluores-
cence for CXCR1 and CD15 was performed with isotype-specific
secondary antibodies (anti-mouse IgG2 biotinylated, 1:100, Caltag,
Burlingame, CA, USA; anti-mouse IgM FITC conjugated, 1:25;
Vector). As negative controls, each antibody was replaced by isotype
controls (not illustrated).
Flow cytometry
For whole blood staining, serum was removed by three washing
steps in isotonic phosphate-buffered saline. In total, 50 ml of packed
whole blood cells or 0.5 106 cells of purified blood mononuclear
cells or lymphocytes from tonsil were used for staining. Cells were
first Fc-receptor-blocked by treatment with 1 mg of human
immunoglobulin G (in phosphate-buffered saline with 0.5% bovine
serum albumin)/105 cells for 15 min at room temperature.
Monoclonal antibodies were then directly added to this reaction
and incubated for 45 min on ice. Antibody combinations were:
phycoerythrin-labeled CXCR1 (Clone 42705, R&D, Minneapolis,
MN, USA) combined with FITC-labeled CD3 (UCHT1, BD
Pharmingen, San Diego, CA, USA) and allophycocyanin-labeled
CD56 (N901/NKH-1, Beckman Coulter, Fullerton, CA, USA) or
FITC-labeled CD19 (HIB19, BD Pharmingen), and APC-labeled
CD14 (TueK4, Caltag); or APC-CD14 and FITC-CD68 (KP1, Dako).
Four marker monoclonal antibody combinations employed: phyco-
erythrin-labeled CXCR1 and pacific blue (PB)-labeled CD3
(UCHT1, Dako) combined with APC-CD56 and FITC-labeled
CD16 (3G8, BD Pharmingen); or APC-CD209 (Clone 120507,
R&D) and FITC-CD68; or APC-CD28 (CD28.2, BD Pharmingen)
and FITC-CD27 (M-T271, BD Pharmingen). Following the staining
procedure, whole blood cells were subjected to a red blood lysis step
using a commercially available whole blood lysing kit. Propidium
iodide (1mg/ml; Sigma Aldrich, Munich, Germany) was added to
the stained samples immediately before acquisition, which employed
either a fluorescence-activated cell sorter Calibur and Cell Quest Pro
software (Becton Dickinson, Mountain View, CA) or CyAn-ADP
(Dakocytomation, Hamburg, Germany) and Summit 4.1 Software.
For analysis, gates were set on PI-negative (viable) cells and on
lymphocytes, neutrophils, or myeloid cells as determined by forward
and sideward scatter.
Isolation of cells
Peripheral blood mononuclear cells were obtained from heparinized
venous blood samples of healthy volunteer donors using Ficoll-
Hypaque (Biochrom, Berlin, Germany) density gradient centrifuga-
tion. The mononuclear cell fraction was collected, washed with
phosphate-buffered saline, counted, and cryopreserved.
For isolation of lymphocytes from tonsil, tissue specimens were
covered with ice-cold N-2-hydroxyethylpiperazine-N[prime]-2-ehane-
sulfonic acid-buffered saline (without Mg2þ and Ca2þ ), minced
into small pieces and passed through a fine wire mesh. Larger
fragments were allowed to settle before supernatant was collected
and passed through a cell strainer of 20mm (BD Falcon, Bedford,
MA, USA). Lymphocytes were counted and cryopreserved in
aliquots.
Real time reverse transcriptase-polymerse chain reaction
To quantify the mRNA expression of CXCL8/IL-8 and the
corresponding receptor CXCR1, we used reverse transcriptase-
polymerse chain reaction as previously described.52 Included were
microsdissected renal biopsies from a multicenter renal biopsy
bank (the European renal cDNA bank). RNAs were from
tumor nephrectomies (n¼ 5), CGN (n¼ 8), lupus nephritis
(n¼ 8), MPGN (n¼ 4), membranous nephropathy (n¼ 6), and
IgA nephropathy (n¼ 7).
Real time reverse transcriptase-polymerse chain reaction was
performed on a TaqMan ABI 7700 Sequence Detection System
(Applied Biosystems, Darmstadt, Germany) using heat-activated
TaqDNA polymerase (Amplitaq Gold, Applied Biosystems, Darm-
stadt, Germany). After an initial hold of 2 min at 501C and 10 min at
951C, the samples were cycled 40 times at 951C for 15 s and 601C for
60 s. Target gene forward and reverse primers and probes for CXCR1
were designed with Primer ExpressTM (Applied Biosystems, Darm-
stadt, Germany): forward primer 50-CGCCAGGCTTACCATCCA-30,
reverse primer 50-CAAACAGCGGCACGATGA-30 and fluorescent-
labeled probe 50-FAM-TCCGCAACACCATCCGCCATT-TAMRA.
Commercially available predeveloped TaqMan assay reagents were
used for the internal standard 18S ribosomal RNA and the target
gene CXCL8/IL-8.
Quantification of the given templates was performed according
to the standard curve method. Serial dilutions of standard cDNA
from a human nephrectomy were included in all PCR runs and
served as standard curve. All measurements were performed in
duplicates. Controls consisting of bidistilled H2O were negative in
all runs.
Evaluation and statistics
Positive cells were counted in up to 15 high-power fields (original
magnification  400, 0.0743 mm2) by an observer blinded to the
diagnosis of the biopsy. The number of glomeruli, and positive cells
per glomeruli were counted for CXCR1, CD15, and CD68. Numbers
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are given as means and standard error of the mean. The statistical
analysis was performed using the InStats program (Version 3.05
for Windows, Intuitive Software for Science, San Diego, CA, USA).
For the comparison of mean numbers, the non-parametric
Mann–Whitney U-test was used. A Po0.05 was considered to be
statistically significant.
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